David V Sheehan

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. doi request reprint Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
    David V Sheehan
    Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, 3515 East Fletcher Ave, Tampa, FL 33613 4706, USA
    J Clin Psychiatry 71:313-26. 2010
  2. ncbi request reprint Paroxetine treatment of generalized anxiety disorder
    David V Sheehan
    College of Medicine, University of South Florida, Tampa, FL 33613 4788, USA
    Psychopharmacol Bull 37:64-75. 2003
  3. ncbi request reprint Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder
    David V Sheehan
    Institute for Research in Psychiatry, Department of Psychiatry, University of South Florida, Tampa, FL 33613 4788, USA
    J Clin Psychiatry 66:34-40. 2005
  4. ncbi request reprint Current approaches to the pharmacologic treatment of anxiety disorders
    David V Sheehan
    University of South Florida College of Medicine, Tampa, FL 33613, USA
    Psychopharmacol Bull 40:98-109. 2007
  5. ncbi request reprint Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study
    David V Sheehan
    University of South Florida College of Medicine, Tampa, FL 33613, USA Electronic address
    J Affect Disord 151:906-13. 2013
  6. doi request reprint Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient
    David V Sheehan
    Clinical and Translational Science Institute, University of South Florida, College of Medicine, 3515 East Fletcher Ave, Tampa, FL 33613, USA
    J Affect Disord 145:83-94. 2013
  7. doi request reprint Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate
    David V Sheehan
    College of Medicine, University of South Florida, Tampa, FL 33613, USA
    Int Clin Psychopharmacol 27:239-48. 2012
  8. ncbi request reprint An open-label study of tiagabine in panic disorder
    David V Sheehan
    University of South Florida College of Medicine, Tampa, FL, USA
    Psychopharmacol Bull 40:32-40. 2007
  9. doi request reprint Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features
    David V Sheehan
    Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, Tampa, Florida 33613, USA
    Int Clin Psychopharmacol 24:61-86. 2009
  10. doi request reprint Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
    David V Sheehan
    University of South Florida College of Medicine, United States
    J Affect Disord 115:376-85. 2009

Detail Information

Publications26

  1. doi request reprint Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
    David V Sheehan
    Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, 3515 East Fletcher Ave, Tampa, FL 33613 4706, USA
    J Clin Psychiatry 71:313-26. 2010
    ....
  2. ncbi request reprint Paroxetine treatment of generalized anxiety disorder
    David V Sheehan
    College of Medicine, University of South Florida, Tampa, FL 33613 4788, USA
    Psychopharmacol Bull 37:64-75. 2003
    ..This article provides an overview of GAD and a discussion of studies of paroxetine treatment in this anxiety disorder...
  3. ncbi request reprint Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder
    David V Sheehan
    Institute for Research in Psychiatry, Department of Psychiatry, University of South Florida, Tampa, FL 33613 4788, USA
    J Clin Psychiatry 66:34-40. 2005
    ..To assess the efficacy and tolerability of controlled-release paroxetine (paroxetine CR) in the treatment of adults with panic disorder...
  4. ncbi request reprint Current approaches to the pharmacologic treatment of anxiety disorders
    David V Sheehan
    University of South Florida College of Medicine, Tampa, FL 33613, USA
    Psychopharmacol Bull 40:98-109. 2007
    ..Preliminary data suggest that tiagabine, the only available SGRI, may also be beneficial in the anxiety disorders. Further research on these novel agents in anxiety disorders is needed...
  5. ncbi request reprint Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study
    David V Sheehan
    University of South Florida College of Medicine, Tampa, FL 33613, USA Electronic address
    J Affect Disord 151:906-13. 2013
    ..This analysis evaluated effects of quetiapine XR maintenance treatment on functioning and sleep in patients with GAD...
  6. doi request reprint Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient
    David V Sheehan
    Clinical and Translational Science Institute, University of South Florida, College of Medicine, 3515 East Fletcher Ave, Tampa, FL 33613, USA
    J Affect Disord 145:83-94. 2013
    ..Anxiety disorders complicate the treatment of bipolar disorder but are seldom the focus of bipolar treatment studies...
  7. doi request reprint Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate
    David V Sheehan
    College of Medicine, University of South Florida, Tampa, FL 33613, USA
    Int Clin Psychopharmacol 27:239-48. 2012
    ..In conclusion, quetiapine XR (50-300 mg/day) monotherapy better maintains overall functioning and sleep quality than placebo in patients with major depressive disorder...
  8. ncbi request reprint An open-label study of tiagabine in panic disorder
    David V Sheehan
    University of South Florida College of Medicine, Tampa, FL, USA
    Psychopharmacol Bull 40:32-40. 2007
    ..Only one patient discontinued tiagabine due to adverse events. These findings suggest that administration of tiagabine may be of little benefit in patients with panic disorder...
  9. doi request reprint Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features
    David V Sheehan
    Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, Tampa, Florida 33613, USA
    Int Clin Psychopharmacol 24:61-86. 2009
    ..Venlafaxine was not superior to fluoxetine or placebo in providing remission...
  10. doi request reprint Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
    David V Sheehan
    University of South Florida College of Medicine, United States
    J Affect Disord 115:376-85. 2009
    ..Although second generation antipsychotics are being used with increasing frequency in bipolar patients, their anxiolytic effects have not been well studied in this population...
  11. ncbi request reprint The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder
    David V Sheehan
    Department of Psychiatry, University of South Florida College of Medicine, Tampa, Florida 33613, USA
    Psychopharmacol Bull 40:63-81. 2007
    ..These results must be viewed in the context of the study limitations including its small size, the lack of independence of groups in a switch study, and the limitations of the diary records used...
  12. ncbi request reprint An evidence-based review of the clinical use of sertraline in mood and anxiety disorders
    David V Sheehan
    University of South Florida College of Medicine, 3515 E Fletcher Avenue, Tampa, FL 33613, USA
    Int Clin Psychopharmacol 24:43-60. 2009
    ....
  13. doi request reprint Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale
    David V Sheehan
    University of South Florida, Tampa, Florida, USA
    Int Clin Psychopharmacol 26:75-83. 2011
    ..The study shows that functional remission does not always move in tandem with symptom remission and provides useful anchor points or rules of thumb for evaluating symptomatic and functional remission in MDD and GAD...
  14. ncbi request reprint Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders
    David V Sheehan
    University of South Florida College of Medicine, Tampa, Florida, USA
    CNS Drugs 22:963-73. 2008
    ....
  15. ncbi request reprint Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine
    David V Sheehan
    University of South Florida College of Medicine, Tampa, FL, USA
    J Clin Psychopharmacol 24:544-8. 2004
    ..This is the first study to directly compare treatment discontinuation rates and health care expenditures of a CR selective serotonin reuptake inhibitors with its IR counterpart...
  16. ncbi request reprint Differences in total medical costs across the SSRIs for the treatment of depression and anxiety
    David V Sheehan
    Department of Psychiatry and Behavioral Medicine, University of South Florida, 4202 E Fowler Avenue, Tampa, FL 33620, USA
    Am J Manag Care 11:S354-61. 2005
    ..Future studies should measure rates of adherence in relation to medical outcomes over an expanded time frame...
  17. pmc Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders
    Keming Gao
    Department of Psychiatry, Mood and Anxiety Clinic in the Mood Disorders Program, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
    Expert Rev Neurother 9:1147-58. 2009
    ..However, in contrast to antidepressants and benzodiazepines, the long-term risk and benefit of atypical antipsychotics in the treatment of GAD is yet to be determined...
  18. ncbi request reprint Improved tolerability and increased length of therapy
    David V Sheehan
    University of South Florida, College of Medicine, USA
    Manag Care 12:23-5. 2003
  19. ncbi request reprint The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder
    David V Sheehan
    University of South Florida College of Medicine, Tampa, FL, USA
    Psychopharmacol Bull 42:5-22. 2009
    ..Overall, the results elucidate the efficacy components and tolerability characteristics previously demonstrated for TzCOAD monotherapy for patients with MDD at the recommended daily dose of 300 mg...
  20. doi request reprint Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine
    David V Sheehan
    College of Medicine, University of South Florida, Tampa, FL, USA
    Hum Psychopharmacol 26:242-51. 2011
    ....
  21. ncbi request reprint The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder
    David V Sheehan
    University of South Florida College of Medicine, Tampa, FL, USA
    Curr Med Res Opin 24:2457-66. 2008
    ..To examine the relationship between global functional impairment and the treatment of anxious symptoms and painful somatic symptoms (PSS) in patients with generalized anxiety disorder (GAD)...
  22. doi request reprint Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale
    Kathy Harnett Sheehan
    University of South Florida College of Medicine, Tampa, FL 33613, USA
    Int Clin Psychopharmacol 23:70-83. 2008
    ..In addition, the percentages with endpoint scores of zero should be reported...
  23. ncbi request reprint Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy
    Jeffery A Lieberman
    Department of Psychiatry, Neurosciences Hospital, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 30:445-60. 2005
    ....
  24. ncbi request reprint The management of panic disorder
    David V Sheehan
    University of South Florida Institute for Research in Psychiatry, Tampa 33613, USA
    J Clin Psychiatry 63:17-21. 2002
    ....
  25. ncbi request reprint Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine
    R Douglas Shytle
    Center for Aging and Brain Repair, Department of Neurosurgery, University of South Florida College of Medicine, 12901 Bruce B Downs Boulevard, Tampa, FL 33613, USA
    Depress Anxiety 16:89-92. 2002
  26. ncbi request reprint Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment
    David V Sheehan
    Department of Psychiatry and Behavioral Medicine, University of South Florida College of Medicine, Tampa, FL, USA
    Manag Care Q 10:21-31. 2002
    ..Assessment of overall cost-effectiveness should not be limited by acquisition costs but should take total healthcare costs into consideration...